Abstract： Objective: To design a subconjunctival implant injection device; to test its performance on rabbits in vivo as the model animal. Methods: A subconjunctival implant injection device was manufactured. Gelatin film was injected via the device into the left eye of rabbits (as the test group), the right eye as the control group just repeat the puncture and insertion actions without implantation of the film. After the implantation, 2 rabbits were selected to be sacrificed at the time points of 0, 1, 2 and 3 d. The eyeballs were removed and the wound healing was observed with hematoxylin-eosin staining. Results: The device with a curvature radius of the 8 mm needle and an inner diameter section of 1.96 mm×0.38 mm. No bleeding at the injection site and no translocation of the gelatin film were observed after injection with this device. The wound healing degree in the same time period between the experimental group and the control group was almost identical without any obvious difference. Conclusions: The injection device is simple and time-saving during film implantation, effectively overcoming the trauma of conventional implant surgery, which might provide new assistance for the clinical application of novel, sustained drug-release formulations.
Liu YC, Peng Y, Lwin NC, et al. A biodegradable, sustained-released, prednisolone acetate microfilm drug delivery system effectively prolongs corneal allograft survival in the rat keratoplasty model. PloS one, 2013, 8(8): e70419. DOI: 10.1371/journal.pone.0070419.
Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: In vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci, 2012, 47(4): 678-685. DOI: 10.1016/ j.ejps.2012.08.008.
[4]
Wang S, Wang M, Liu Y, et al. Effect of Rapamycin Microspheres in Sjögren Syndrome Dry Eye: Preparation and Outcomes. Ocul Immunol Inflamm, 2019, 27(8): 1357-1364. DOI: 10.1080/09273948.2018.1527369.
[5]
Wu J, Nasseri MA, Eder M, et al. The 3D eyeball FEA model with needle rotation. 3rd APCBEE Procedia, 2013, 7: 4-10. DOI: 10.1016/j.apcbee.2013.08.003.
Nguyen CL, Chen TS, Tran K, et al. Simultaneous Subconjunctival Triamcinolone and Bevacizumab Injections for Management of Blepharokeratoconjunctivitis in Children. Case Rep Ophthalmol Med, 2018, 2018: 2602487. DOI: 10.1155/2018/2602487.
[13]
Tsai SH, Lin YC, Hsu HC, et al. Subconjunctival injection of fluconazole in the treatment of fungal alternaria keratitis. Ocul Immunol Inflamm, 2016, 24(1): 103-106. DOI: 10.3109/09273948.2014.916308.
[14]
Soiberman U, Kambhampati SP, Wu T, et al. Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation. Biomaterials, 2017, 125: 38-53. DOI: 10.1016/j.biomaterials.2017.02.016.
Wang J, Jiang A, Joshi M, et al. Drug delivery implants in the treatment of vitreous inflammation. Mediators Inflamm, 2013, 2013: 780634-780638. DOI: 10.1155/2013/780634.
[17]
Tanito M, Okada A, Mori Y, et al. Subconjunctival implantation of ologen Collagen Matrix to treat ocular hypotony after filtration glaucoma surgery. Eye (Lond), 2017, 31(10): 1475- 1479. DOI: 10.1038/eye.2017.98.
Lee SS, Hughes P, Ross AD, et al. Biodegradable implants for sustained drug release in the eye. Pharm Res, 2010, 27(10): 2043-2053. DOI: 10.1007/s11095-010-0159-x.
浙公网安备 33030202001892号